The U.S. drug regulator declined to approve a combination of Merck & Co. Inc.’s blockbuster cancer drug Keytruda and Eisai Co. Ltd.’s Lenvima as the first line of treatment in patients with liver cancer.
The U.S. Food and Drug Administration approved Roche’s immunotherapy Tecentriq in combination with the Swiss drugmaker’s Avastin for the most common kind of liver cancer.
Roche’s immunotherapy Tecentriq combined with the Swiss drugmaker’s Avastin medicine helped people with the most common form of liver cancer to live longer than with an older drug from Germany’s Bayer.
Researchers with the Hubrecht Institute in Utrecht, Netherlands and Radboud University in Nijmegen, Netherlands, developed a human model using organoids to evaluate the function of specific genes commonly mutated in liver cancer.
Gilead Sciences Inc. will partner with privately held insitro to develop therapies for a fatty liver disease called NASH.
Merck & Co. Inc.’s blockbuster anti-PD-1 immunotherapy Keytruda failed a late-stage trial’s main goals of slowing disease progression and extending the life of patients with a common type of liver cancer.
China has become one of the most important markets for pharma companies, given the vast patient population and the rising cancer rates, and western pharmaceutical companies are making greater inroads there.
Eisai and Merck announced that the U.S. FDA approved the kinase inhibitor Lenvima (lenvatinib) for the first-line treatment of patients with unresectable hepatocellular carcinoma.
Japan’s Eisai Co. Ltd. will price the company’s cancer drug Lenvima at about $16,000 for a month’s supply before discounts, after the U.S. Food and Drug Administration approved the product’s use in patients with a common form of liver cancer.
The U.S. government is considering setting new payment methods aimed at curbing costs for Medicare and Medicaid coverage of breakthrough medical treatments with very high prices, particularly novel gene-based therapies for cancer and other diseases, a top health official said.